These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
41. Clinical evaluation of centbutindole as an anti-psychotic agent. Doongaji DR; Sheth AS; Paul T; Parikh RM; Vahora SA; Apte JS; Desai NK; Upadhaya AK; Satoskar RS Indian J Med Res; 1983 Jul; 78():126-33. PubMed ID: 6139336 [No Abstract] [Full Text] [Related]
42. Cysteamine, a pro-BDNF drug, as an adjunctive treatment for schizophrenia. Buckley PF; Miller BJ; Pillai A; Kirkpatrick B Schizophr Res; 2014 Sep; 158(1-3):268-9. PubMed ID: 25052781 [No Abstract] [Full Text] [Related]
43. Ondansetron in treatment of schizophrenia. White A; Corn TH; Feetham C; Faulconbridge C Lancet; 1991 May; 337(8750):1173. PubMed ID: 1674058 [No Abstract] [Full Text] [Related]
44. The influence of group therapy on schizophrenia. Malm U Acta Psychiatr Scand Suppl; 1982; 297():1-65. PubMed ID: 6126069 [No Abstract] [Full Text] [Related]
45. CT scans and neuropsychological tests as predictors of clinical response in schizophrenics. Smith RC; Largen J; Calderon M; Schoolar J; Shvartsburd A; Ravichandran GK Psychopharmacol Bull; 1983; 19(3):505-9. PubMed ID: 6138798 [No Abstract] [Full Text] [Related]
47. Mortality in schizophrenia. Hasnain M; Vieweg WV; Mezuk B J Psychopharmacol; 2011 Jun; 25(6):846-7. PubMed ID: 21421641 [No Abstract] [Full Text] [Related]
48. Response to Kujawa et al. letter-to-the-editor. Sethuraman G; Taylor CC; Enerson M; Dunayevich E Schizophr Res; 2006 May; 84(1):172-3. PubMed ID: 16563702 [No Abstract] [Full Text] [Related]
49. Clinical trials for negative symptoms--emerging directions and unresolved issues. Marder SR; Rabinowitz J; Kapur S Schizophr Res; 2013 Nov; 150(2-3):327. PubMed ID: 24209763 [No Abstract] [Full Text] [Related]
50. Schizophrenia drug shines in phase III. Kingwell K Nat Rev Drug Discov; 2022 Oct; 21(10):702. PubMed ID: 36045284 [No Abstract] [Full Text] [Related]
51. A pilot study of ST-155 (catapres) in chronic schizophrenics. Sugerman AA J Clin Pharmacol J New Drugs; 1967; 7(4):226-8. PubMed ID: 5231439 [No Abstract] [Full Text] [Related]
53. Proceedings: Butaclamol in the treatment of schizophrenia--a comparison of two treatment methods. Imaz F; Ban TA; Lehmann HE Psychopharmacol Bull; 1976 Jan; 12(1):31-4. PubMed ID: 1826 [No Abstract] [Full Text] [Related]
54. Clinical effectiveness of piperacetazine injection in schizophrenic patients: a controlled study. Kulkarni AS Adv Biochem Psychopharmacol; 1974; 9(0):691-9. PubMed ID: 4151770 [No Abstract] [Full Text] [Related]
55. Antipsychotic effects of AL 1965. Sathananthan G; Mir P; Gershon S Curr Ther Res Clin Exp; 1976 May; 19(5):516-9. PubMed ID: 7435 [No Abstract] [Full Text] [Related]
56. Sertindole: a review of clinical efficacy. Kane JM Int Clin Psychopharmacol; 1998 Mar; 13 Suppl 3():S59-63; discussion S63-4. PubMed ID: 9690972 [TBL] [Abstract][Full Text] [Related]
57. Do we need another atypical antipsychotic? Kasper S Eur Neuropsychopharmacol; 2008 Aug; 18 Suppl 3():S146-52. PubMed ID: 18511242 [TBL] [Abstract][Full Text] [Related]